問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

涂智彥Tu, Chih-Yen
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years

  • D7855@mail.cmuh.org.tw

Recruiting Trial

72Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

涂智彥

China Medical University Hospital

Division of Thoracic Medicine

List

109Cases

2024-11-29 - 2027-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2015-02-25 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Terminated10Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2020-11-30 - 2023-12-31

Phase IV

andomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma

  • Condition/Disease

    asthma

  • Test Drug

    Dupilumab

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2021-09-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2017-04-01 - 2020-06-01

Phase III

Open-label extension study to evaluate the long-term safety and tolerability of dupilumab inpatients with asthma who participated in a previous dupilumab asthma clinical study

  • Condition/Disease

    asthma

  • Test Drug

    Dupilumab

Participate Sites
4Sites

Terminated3Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

鍾啟禮
Taipei Medical University Hospital

Division of Thoracic Medicine

2008-10-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated1Sites

Suspended1Sites

2015-07-01 - 2020-12-31

Phase II

Multicenter, open-label, single arm, Phase II study in advanced non-small cell lung cancer；Subtitle:A multicenter, open-label, single arm Phase II study to evaluate safety and efficacy of ONO-4538 in stage IIIB/IV or recurrent non-small cell lung cancer patients who are unsuited to radical radiotherapy and resistant to a platinum-base chemotherapeutic regimen.

  • Condition/Disease

    stage IIIB/IV or recurrent non-small cell lung cancer

  • Test Drug

    Opdivo®

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2019-06-01 - 2022-12-31

Phase II

A PHASE 2, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, CONTROLLED STUDY OF PEMETREXED MAINTENANCE WITH OR WITHOUT ADXS11-001 IMMUNOTHERAPY IN SUBJECTS WITH HUMAN PAPILLOMAVIRUS-POSITIVE, NON-SQUAMOUS, NONSMALL CELL LUNG CARCINOMA FOLLOWING FIRST-LINE INDUCTION CHEMOTHERAPY

  • Condition/Disease

    LUNG CARCINOMA

  • Test Drug

    ADXS11-001

Participate Sites
9Sites

Terminated9Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2015-07-01 - 2015-12-12

Others

A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist (STRATOS 1)

  • Condition/Disease

    Asthma Inadequately Controlled

  • Test Drug

    Tralokinumab

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

1 4 5 6 7 8 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB